GORTEC, known as Head and Neck Radiation Oncology Group, today announced that the randomized Phase 3 NIVOPOSTOP GORTEC ...

The FDA has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), a new subcutaneous injection formulation of Opdivo.

The FDA approved subcutaneous nivolumab for solid tumors, tiselizumab for advanced gastric and GEJ cancers, and key 2024 breast cancer breakthroughs are reviewed. Experts provide perspective on ...

Raymond Y. Huang, MD, Ph.D., of the Department of Radiology at Brigham and Women's Hospital, is the corresponding author of a ...

The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for ...

Raymond Y. Huang, MD, Ph.D., of the Department of Radiology at Brigham and Women’s Hospital, is the corresponding author of a paper published in the Journal of Clinical Oncology, “Comparative Analysis ...

FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.

Almost exactly 10 years after the FDA’s initial FDA approval for Bristol Myers Squibb’s Opdivo as the first PD-1 inhibitor in ...

The FDA has approved subcutaneous nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) to treat a range of solid tumor malignancies.

The FDA approved a subcutaneous injection version of Bristol Myers Squibb nivolumab and hyaluronidase-nvhy for the treatment of several cancers including melanoma, non-small cell lung cancer and renal ...

Becomes the first subcutaneously administered PD-1 inhibitor.

More research is needed to refine treatment strategies and identify predictive biomarkers for patient selection, according to researchers.